Does Risk of Progression from Barrett’s Esophagus to Esophageal Adenocarcinoma Change Based on the Number of Non-dysplastic Endoscopies?
暂无分享,去创建一个
A. Thrift | R. Turkington | B. Johnston | H. Coleman | D. McManus | L. Anderson | Andrew T. Kunzmann | A. Kunzmann | D. Mcmanus
[1] I. Nagtegaal,et al. Incidence of Progression of Persistent Nondysplastic Barrett's Esophagus to Malignancy , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[2] A. Gavin,et al. ‘Missed’ oesophageal adenocarcinoma and high-grade dysplasia in Barrett’s oesophagus patients: A large population-based study , 2018, United European gastroenterology journal.
[3] Matthew Banks,et al. Quality standards in upper gastrointestinal endoscopy: a position statement of the British Society of Gastroenterology (BSG) and Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS) , 2017, Gut.
[4] H. El‐Serag,et al. The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett’s Esophagus , 2017, The American Journal of Gastroenterology.
[5] Kenneth K Wang,et al. Persistence of Nondysplastic Barrett’s Esophagus Is Not Protective Against Progression to Adenocarcinoma , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[6] I. Nagtegaal,et al. 535 Incidence of Malignant Progression in Persistent Nondysplastic Barrett's Esophagus, a Dutch Nationwide Cohort Study , 2017 .
[7] P. Martinez,et al. Dynamic clonal equilibrium and predetermined cancer risk in Barrett's oesophagus , 2016, Nature Communications.
[8] Nicholas J Shaheen,et al. ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus , 2016, The American Journal of Gastroenterology.
[9] S. Menon,et al. How commonly is upper gastrointestinal cancer missed at endoscopy? A meta-analysis , 2014, Endoscopy International Open.
[10] D. Whiteman,et al. Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett's esophagus. , 2014, Gastrointestinal endoscopy.
[11] A. Gavin,et al. Symptoms and Endoscopic Features at Barrett's Esophagus Diagnosis: Implications for Neoplastic Progression Risk , 2013, The American Journal of Gastroenterology.
[12] Carissa A. Sanchez,et al. Temporal and Spatial Evolution of Somatic Chromosomal Alterations: A Case-Cohort Study of Barrett's Esophagus , 2013, Cancer Prevention Research.
[13] Rebecca C Fitzgerald,et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus , 2013, Gut.
[14] Prateek Sharma,et al. Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort. , 2013, Gastroenterology.
[15] H. Sørensen,et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. , 2011, The New England journal of medicine.
[16] A. Gavin,et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. , 2011, Journal of the National Cancer Institute.
[17] A. Gavin,et al. Increasing incidence of Barrett’s oesophagus: a population-based study , 2011, European Journal of Epidemiology.
[18] J. Barendregt,et al. Is endoscopic surveillance for non‐dysplastic Barrett's esophagus cost‐effective? Review of economic evaluations , 2011, Journal of gastroenterology and hepatology.
[19] M. Coleman,et al. Guidelines on confidentiality for population-based cancer registration , 2005, Asian Pacific journal of cancer prevention : APJCP.